Quick Dispatch:
Your soul trial oral semaglutide cardiovascular outcomes 2024 2025 results Rethinking the Standard of Care: orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your soul trial oral semaglutide cardiovascular outcomes 2024 2025 results Rethinking the Standard of Care: ships.
Need Help?
Questions about soul trial oral semaglutide cardiovascular outcomes 2024 2025 results Rethinking the Standard of Care:, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for soul trial oral semaglutide cardiovascular outcomes 2024 2025 results Rethinking the Standard of Care: in your area.
Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial
20.21
Trial Scorecard: SOUL
20.37
Forecasting Trial Milestones: A Predictive Analysis for Early Termination of the SOUL Study | Diabetes Therapy
28.32
In patients with cardiovascular disease and overweight or obesity but no diabetes, semaglutide was superior to placebo in lowering the risk of major adverse cardiovascular events at a mean follow-up of 39.8
25.82
Oral Semaglutide in High-Risk Type 2 Diabetes: Cardiovascular Benefit Confirmed in the SOUL Trial
21.13
SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes
22.64
Canadian Perspectives 2025 Whiteboard on the SOUL Trial
24.62
